Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of Genedata Screener® 11, a single-platform screening data analysis system with built-in business logic for standardizing and automating screening workflows. The new Genedata Screener now supports compound combination screens to analyze compound synergy effects as well as high throughput flow cytometry including cell sub-population analysis. Integrating with any plate-based instrument, Genedata Screener supports High, Medium and Low Throughput Screens, High Content Screening (HCS), Ion Channel Screening, Label-free (including thermal shift), and other assay technologies. Now, it also can be used in the cloud to enable pharma-CRO collaboration on the same analysis platform. Genedata Screener 11 will be demonstrated April 9 -11 at the Bio-IT World Conference & Expo (World Trade Center; Booth #228).
Realizing the Promise of Compound Combination Screening
Compound Combination Screening holds the promise of lowering costs for drug discovery while delivering significantly improved drug therapies for illnesses such as cancer, diabetes, and infectious diseases. Today’s instrumentation enables high-throughput Compound Combination Screening experiments measuring, for example, 200 or more combinations across several cell lines. Data analysis, however, for combination experiments remains a major bottleneck as the specifics of combination screening are not fully supported by current screening data analysis systems. The Genedata Screener Compound Synergy Extension removes this bottleneck to enable full realization of the experimental capacity. Compound Synergy Extension can easily be added to an existing Genedata Screener installation, which:
• Eliminates manual data processing of compound synergy data
• Imports information for multiple compounds per well from files or database systems
• Fits mono-therapeutic Dose Response Curves
• Calculates Synergy Scores using the Loewe and Highest Single Agent models
• Visualizes combination effects in heat maps (e.g. for measured, modeled and excess activity)
New Applications for Single-Cell Analysis
Genedata Screener 11 also features an enhanced Cell Population Extension for improved support of high throughput flow cytometry, cell cycle and similar experiments that define and display cell sub-populations. In a single view, researchers can define, manage, and display cell sub-populations and use cell sub-populations as input for cell-to-well data aggregation. These capabilities streamline processing of cell-based experiments and enable corporate-wide management of single-cell data, at an unprecedented scale.
Collaboration in the Cloud
Enabling new levels of collaborative research and screening data analysis, Genedata Screener 11 features advanced support for encrypted data transmission and authentication. Fully cloud-compliant, Genedata Screener 11 standardizes data analysis across different organizations and multiple sites. With the Genedata Screener server in the cloud, users run their clients in the local environment: while data transfer to and from the cloud is determined by the bandwidth of the network connection, Genedata Screener data processing speed and unique interactive capabilities persist.
“Genedata Screener 11 will unleash new opportunities in lead optimization and target validation by giving pharmaceutical and biotechnology researchers a standardized platform on which they can efficiently visualize and explore compound combinations at unprecedented processing speed and with unsurpassed result quality,” said Dr. Othmar Pfannes, CEO of Genedata. “The ongoing innovation we are able to consistently deliver with each version of Genedata Screener is a result of our partnerships with industry leaders and our significant investments in and commitment to Genedata R&D.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. www.genedata.com.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.